Jilin Aodong Pharmaceutical Group Co., Ltd.
000623
Rangering i aksjer
#4841
Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally... Jilin Aodong Pharmaceutical Group Co., Ltd. operates in China, principally focusing on the production and distribution of a broad spectrum of pharmaceutical goods. Its product line encompasses various drug forms like oral liquids, injections, capsules, granules, pills, and tablets, as well as traditional Chinese herbal medicines, powders, syrups, and spirits. The company also produces specialized medicinal products, including enzymes, biochemical drugs, and plant-based chemical medicines. In addition to its core pharmaceutical activities, Jilin Aodong diversifies its operations across several other sectors. These include highway construction and toll management, animal husbandry, the creation of specialty chemicals, and the provision of heat and water. The company further engages in the wholesale, retail, and distribution of medicines, packaging design and printing, the manufacturing of medicinal packaging materials, and delivers information consulting and advertising design solutions. Founded in 1957, its corporate headquarters are situated in Dunhua, China.
Aksjekurs
$2.53
Markedsverdi
$3.02B
Endring (1 dag)
-0.76%
Endring (1 år)
-11.34%
Land
CN
Handel Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Kategori
Healthcare
Inntekter for Jilin Aodong Pharmaceutical Group Co., Ltd. (000623)
Inntekter i Jun 2026 TTM: $324.58M
Ifølge de nyeste økonomiske rapportene til Jilin Aodong Pharmaceutical Group Co., Ltd. er selskapets nåværende inntekter (TTM) $324.58M. I 2023 hadde selskapet inntekter på $487.26M en økning sammenlignet med inntektene i 2022, som var $415.81M. Inntektene er det totale beløpet et selskap genererer fra salg av varer eller tjenester. I motsetning til fortjeneste trekkes ingen kostnader fra.
Inntektshistorikk for Jilin Aodong Pharmaceutical Group Co., Ltd. fra 2000 til 2026
Inntekter ved slutten av hvert år
| År | Inntekter | Endre |
|---|---|---|
| 2026 (TTM) | $324.58M | -9.25% |
| 2024 | $357.66M | -26.60% |
| 2023 | $487.26M | 17.18% |
| 2022 | $415.81M | 14.72% |
| 2021 | $362.46M | 5.16% |
| 2020 | $344.67M | -22.29% |
| 2019 | $443.52M | -8.22% |
| 2018 | $483.25M | 5.62% |
| 2017 | $457.53M | 16.07% |
| 2016 | $394.17M | 9.63% |
| 2015 | $359.54M | -0.59% |
| 2014 | $361.66M | 12.10% |
| 2013 | $322.61M | 39.17% |
| 2012 | $231.80M | 27.60% |
| 2011 | $181.66M | 7.70% |
| 2010 | $168.67M | 12.29% |
| 2009 | $150.21M | 10.47% |
| 2008 | $135.97M | 17.47% |
| 2007 | $115.75M | 17.31% |
| 2006 | $98.67M | 3.79% |
| 2005 | $95.06M | -4.15% |
| 2004 | $99.18M | 21.83% |
| 2003 | $81.41M | 17.43% |
| 2002 | $69.33M | 28.70% |
| 2001 | $53.87M | 41.79% |
| 2000 | $37.99M | 0.00% |
Inntekter for lignende selskaper eller konkurrenter
| Selskap | Inntekter | Forskjell i inntekter | Land |
|---|---|---|---|
| - | - |
DE
|
|
| - | - |
DE
|
|
| - | - |
JP
|
|
| - | - |
CH
|
|
| $6.61B | 1,936.98% |
IN
|
